BriaCell Therapeutics Corp.

BriaCell Therapeutics Corp. is a clinical-stage immuno-oncology company developing targeted cellular immunotherapies for cancer treatment. Its lead candidate, Bria-IMT™, is a patented, off-the-shelf, cell-based immunotherapy being evaluated in a pivotal Phase 3 study for metastatic breast cancer. BriaCell also develops Bria-OTS™, a platform of personalized off-the-shelf immunotherapies, which is undergoing Phase 1/2 clinical studies targeting multiple cancers, including breast and prostate cancer. The company focuses on enhancing the immune system's ability to identify and destroy cancer cells while minimizing harm to healthy tissue.